Routine non-ABO blood group antigen genotyping in sickle cell disease: The new frontier in pretransfusion testing?

Transfusion

Volumn 55, Issue 6, 2015, Pages 1374-1377

  Tormey, Christopher A ^a,b   Hendrickson, Jeanne E ^b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Department of Laboratory Medicine ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; RHESUS ANTIGEN;

ALLOIMMUNIZATION; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; BLOOD TRANSFUSION REACTION; CLINICAL PRACTICE; DONOR SELECTION; ERYTHROCYTE TRANSFUSION; GENOTYPE; HUMAN; IMMUNOGENICITY; MORBIDITY; REVIEW; SEROLOGY; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; ERYTHROCYTE; FEMALE; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; MOLECULAR TYPING; PROCEDURES;

ANEMIA, SICKLE CELL; ERYTHROCYTES; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MOLECULAR TYPING;

EID: 84931353914     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13065     Document Type: Review

References (40)

1. Tormey CA, Fisk J, Stack G,. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48: 2069-76.
2. Cheng CK, Lee CK, Lin CK,. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion 2012; 52: 2220-4.
3. Sanz C, Nomdedeu M, Belkaid M, et al., Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013; 53: 710-50.
4. Aly R, El-sharnoby MR, Hagag AA,. Frequency of red cell alloimmunization in patients with sickle cell anemia in an Egyptian referral hospital. Transfus Apher Sci 2012; 47: 253-7.
5. Olujohungbe A, Hambleton I, Stephens L, et al., Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001; 113: 661-5.
6. Aygun B, Padmanabhan S, Paley C, et al., Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
7. Vichinsky EP, Earles A, Johnson RA, et al., Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-21.
8. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2012. Silver Spring (MD): US Food and Drug Administration; 2014 [cited 2015 Jan 8]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm
9. Serious Hazards of Transfusion Steering Committee. Serious Hazards of Transfusion: annual reports and summaries 2014. Manchester (UK): SHOT Office; 2014 [cited 2015 Jan 8]. Available from: http://www.shotuk.org/shot-reports/
10. Hendrickson JE, Tormey CA, Shaz BH,. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014; 28: 137-44.
11. Tormey CA, Stack G,. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49: 505-12.
12. Rosse WF, Gallagher D, Kinney TR, et al., Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood 1990; 76: 1431-7.
13. Harm SK, Yazer MH, Monis GF, et al., A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014; 141: 256-61.
14. Talano JA, Hillery CA, Gottschall JL, et al., Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111: e661-5.
15. Noizat-Pirenne F,. Relevance of alloimmunization in haemolytic transfusion reaction in sickle cell disease. Transfus Clin Biol 2012; 19: 132-8.
16. US Department of Health and Human Services; National Institutes of Health; National Heart, Lung and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014. Washington (DC): US Department of Health and Human Services; National Institutes of Health; National Heart, Lung and Blood Institute; 2014 [cited 2015 Jan 8]. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines/
17. Osby M, Shulman IA,. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129: 190-3.
18. Flegel WA, Castilho L, Delaney M, et al., Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013. Blood Transfus 2014 [Epub ahead of print; doi: 10.2450/2014.].
19. Anstee DJ,. Red cell genotyping and the future of pretransfusion testing. Blood 2009; 114: 248-56.
20. Chou ST, Westhoff CM,. The role of molecular immunohematology in sickle cell disease. Transfus Apher Sci 2011; 44: 73-9.
21. Matteocci A, Pierelli L,. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang 2014; 106: 197-208.
22. Casas J, Friedman DF, Jackson T, et al., Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015; 55: 000-00.
23. Vichinsky EP, Luban NL, Wright E, et al,., Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-92.
24. Sakhalkar VS, Roberts K, Hawthorne LM, et al., Allosensitization in patients receiving multiple blood transfusions. Ann N Y Acad Sci 2005; 1054: 495-9.
25. Lasalle-Williams M, Nuss R, Le T, et al., Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-9.
26. Mijovic A, Perera IG, Thein SL,. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom. Transfusion 2013; 53: 3279-80.
27. O'Suoji C, Liem RI, Mack AK, et al., Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013; 60: 1487-91.
28. Chou ST, Jackson T, Vege S, et al., High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-71.
29. Miller ST, Kim HY, Weiner DL, et al., Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013; 53: 704-9.
30. Silvy M, Di Cristofaro J, Beley S, et al., Identification of RHCE and KEL alleles in large cohorts of Afro-Caribbean and Comorian donors by multiplex SNaPshot and fragment assays: a transfusion support for sickle cell disease patients. Br J Haematol 2011; 154: 260-70.
31. Silvy M, Tournamille C, Babinet J, et al., Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 2014; 99: e115-7.
32. Unni N, Peddinghaus M, Tormey CA, et al., Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 2014; 54: 98-103.
33. Castro O, Sandler SG, Houston-Yu P, et al., Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002; 42: 684-90.
34. Friedman DF, Keller MA, Vege S, et al., Automated RH genetic matching applied to African American donors and patients with sickle cell disease [abstract]. Transfusion 2014; 54: 30A.
35. Klapper E, Zhang Y, Figueroa P, et al., Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 2010; 50: 536-46.
36. Kacker S, Ness PM, Savage WJ, et al., Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54: 86-97.
37. Gehrie EA, Tormey CA,. The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders. Transfus Med Hemother 2014; 41: 420-9.
38. Ryder AB, Zimring JC, Hendrickson JE,. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother 2014; 41: 406-19.
39. Tatari-Calderone Z, Tamouza R, Le Bouder GP, et al., The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol 2013; 2013: 937846.
40. Fasano RM, Booth GS, Miles M, et al., Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015; 168: 291-300.